Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Nebraska Children's Hospital Researchers Publish Study Demonstrating Successful Use of Ascents® Clinical Aromatherapy to Decrease Pain and Nausea, Improve Mood

Dr. Meaghann Weaver of Children's Hospital & Medical Center (Omaha, Nebraska) recently published the results of her palliative care study utilizing Aeroscena®'s Ascents®-brand clinical aromatherapy inhalers in Cambridge University Press' journal Palliative and Supportive Care. Researchers found that the three Ascents aromatherapy formulas used in the study represented an effective supportive care intervention for pediatric patients experiencing pain, nausea, and anxiety.


News provided by

Aeroscena

Aug 27, 2019, 12:00 ET

Share this article

Share toX

Share this article

Share toX

Ascents Personal Clinical Aromatherapy Inhalers
Ascents Personal Clinical Aromatherapy Inhalers

CLEVELAND, Aug. 27, 2019 /PRNewswire-PRWeb/ -- New research[1] carried out by Dr. Meaghann Weaver at Children's Hospital & Medical Center (Omaha, Neb.) has demonstrated that Aeroscena's Ascents-brand clinical aromatherapy formulas represent an effective supportive care intervention for pediatric patients experiencing pain, nausea and anxiety.

Entitled, "Aromatherapy improves nausea, pain, and mood for patients receiving pediatric palliative care symptom-based consults: A pilot design trial," and published in Cambridge University Press's academic journal "Palliative and Supportive Care," the study utilized three distinct Ascents clinical aromatherapy formulas: Calm No. 34, Nausea Relief No. 44, and Focus No. 04. Personal inhaler sachets of each formula were tested as supportive care interventions to decrease pediatric patients' experience of stress/anxiety, nausea and emesis, and pain, respectively.

Dr. Weaver concluded that aromatherapy represents a feasible, implementable supportive care intervention for pediatric patients receiving palliative care consults for symptom burden including nausea, pain and anxiety.

Post this

Ascents Inhalers: A Unique Aromatherapy Delivery System Designed for the Needs of Clinical Environments

In selecting the mode of aromatherapy delivery, the pediatric palliative care team engaged in an extensive review of aromatherapy product formats used in various health care settings. While many previous studies utilized vials of liquid essential oils, concern for contamination, dermatologic impact, accidental ingestion, and spills led Dr. Weaver's team to Ascents inhalers. Ascents' sachet format of aromatherapy was selected because of its individual, localized, and non-topical use, as well as overall high safety profile and minimal likelihood of eliciting an allergic reaction due to the oils' distillation processes. Additionally, the sachets adhere to rigorous manufacturing purity, safety and quality standards; their unique design enables consistent dosing and preservation of essential oils; and they are easy to use, even for those patients with limited physical ability, strength, or range of motion.

Once chosen, Ascents inhalers were presented to the hospital infection prevention team and value analysis team for their review and approval prior to the study's start.

The Study: Objective, Results and Conclusions

The objective of Dr. Weaver's study was to investigate the role of aromatherapy in supportive symptom management for pediatric patients receiving palliative care. The research aimed to measure the impact of aromatherapy using validated child-reported nausea, pain, and mood scales 5 minutes and 60 minutes after aromatherapy exposure.

Symptom burden was sequentially assessed at 5 and 60 minutes using the Baxter Retching Faces (BARF) scale for nausea, the Wong-Baker FACES scale for pain, and the Children's Anxiety and Pain Scale (CAPS) for anxious mood. At 5 minutes, significant improvements were reported for each of the three symptom sets, and remained improved at 60 minutes post-intervention.

Based on the study's strong, positive results, Dr. Weaver concluded that aromatherapy represents a feasible, implementable supportive care intervention for pediatric patients receiving palliative care consults for symptom burden including nausea, pain and anxiety.

"We could not be more pleased with the outcomes of Dr. Weaver's study," said Mark Kohoot, Founder and CEO of Aeroscena. "Knowing that our products are effective in providing comfort care -- especially to children -- gives us great pride, and we will continue to utilize our unparalleled research platform to further the scientific understanding of phyto-pharmaceuticals for use in clinical environments."

[1]Weaver MS, Robinson J, Wichman C (2019). Aromatherapy improves nausea, pain, and mood for patients receiving pediatric palliative care symptom-based consults: A pilot design trial. Palliative and Supportive Care, 1–6.

About Aeroscena®

Established in 2010, Aeroscena is the corporate research and development organization behind Ascents®, the leading brand of therapeutic phyto-inhalants™. Aeroscena has developed the first scientifically-recognized platform for essential oils R&D. Ascents-branded clinical aromatherapy formulas are the only aromatherapy products that are recommended by doctors, used by hospitals®. Aeroscena is located in the Cleveland Clinic Global Cardiovascular Innovations Center in Cleveland, OH. For more information about Ascents, visit https://www.shopascents.com. For more information about Aeroscena®, visit https://www.aeroscena.com.

About Children's Hospital and Medical Center

Children's Hospital & Medical Center is the only full-service, pediatric health care center in Nebraska, providing expertise in more than 50 pediatric specialty services to children across a five-state region and beyond. Children's is home to Nebraska's only Level IV regional Newborn Intensive Care Unit and the state's only Level II Pediatric Trauma Center. A regional heart center, it also offers expertise in pediatric heart transplantation. Children's is recognized as a 2019-20 Best Children's Hospital by U.S. News & World Report in five pediatric specialties: Cardiology and Heart Surgery, Pulmonology, Gastroenterology & GI Surgery, Orthopedics and Diabetes & Endocrine Disorders. Visit us online at ChildrensOmaha.org.

SOURCE Aeroscena

Modal title

Ascents Nausea Relief No. 44 Personal Aromatherapy Inhaler
Ascents Nausea Relief No. 44 Personal Aromatherapy Inhaler
Ascents Calm No. 34 Personal Aromatherapy Inhaler
Ascents Calm No. 34 Personal Aromatherapy Inhaler
Ascents Focus No. 04 Personal Aromatherapy Inhaler
Ascents Focus No. 04 Personal Aromatherapy Inhaler
Aeroscena®'s World Headquarters in the Cleveland Clinic GCIC
Aeroscena®'s World Headquarters in the Cleveland Clinic GCIC
Ascents Nausea Relief No. 44 Personal Aromatherapy Inhaler Ascents Calm No. 34 Personal Aromatherapy Inhaler Ascents Focus No. 04 Personal Aromatherapy Inhaler Aeroscena®'s World Headquarters in the Cleveland Clinic GCIC

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.